Intravenous administration of the anti-interleukin-6 (IL-6) agent tocilizumab (Actemra, Genentech) is well-tolerated in patients with non-infectious uveitis involving the posterior segment and showing promising efficacy, according to interim outcomes reported by Quan Dong Nguyen, MD.
Lifitegrast ophthalmic solution 5.0% (Shire Pharmaceuticals) administered twice daily for 1 year appeared safe and well-tolerated with no unexpected adverse events in a study.
Ultrathin Descemet’s stripping automated endothelial keratoplasty (DSAEK) is associated with faster visual recovery and better visual acuity in a study compared ultrathin with standard DSAEK.
Treatment with red light technology resulted in a significant improvement in the tear break-up time in the vast majority of patients. This may be a future light treatment for the improvement of dry eye disease in patients with meibomian gland dysfunction.
The natural triglyceride form of omega-3 is an excellent treatment option for dry eye disease.
Topometric and tomographic parameters helped researchers detect keratoconus in a study, but the integration of curvature and 3D analysis is needed to identify milder forms of ectatic corneal disease.
Corneal collagen crosslinking with riboflavin works well but requires further exploration to identify the best approach for various types of patients.
Like bevacizumab and ranibizumab, aflibercept has been shown to be effective in treating radiation retinopathy. In a study, patients experienced improved visual acuity and resolution of cystoid macular edema.
Implantation of a silicone oil-filled accommodating IOL (FluidVision, PowerVision) provides 3 to 4 D of accommodation along with excellent distance, intermediate, and near vision-all of which remain stable during follow-up to 2 years, said Louis D. Nichamin, MD.
Use of intraoperative aberrometry to select IOL power results in improved refractive outcomes in eyes that have a history of hyperopic LASIK, according to the results of a retrospective study reported by Dan B. Tran, MD.
The Primary Open-Angle African American Glaucoma Genetics (POAAGG) study is an ongoing 5-year NIH-funded study designed to elucidate the genetic architecture and comorbidities associated with POAG in African Americans, said Joan M. O’Brien, MD.
Ophthalmology Times is pleased to announce the winner of the 2015 Resident Writers Award Program, sponsored by Allergan.
A review of bilateral, same-day cataract surgery cases performed over a 5-year period at Kaiser Permanente centers in California identified a very low rate of complications, said Neal H. Shorstein, MD.
Retina specialists and comprehensive ophthalmologists should identify full thickness macula holes and, generally, recommend a vitrectomy to close them and improve vision.
A small study of using a new contact lens to treat corneal edema after cataract surgery reported positive results.
Chronic dry eye is underdiagnosed and undertreated, but careful observation, good listening skills, and proven treatment approaches can help patients achieve better vision.
T. L. Dawson, MD, writes about his experiences with enhanced bioavailable and non-irritating testosterone eye drops for the treatment of dry eye disease.
Alphaeon Corp. announced it has entered into a definitive agreement with PhysIOL SA, of Belgium, to jointly develop and commercialize an exclusive Alphaeon-branded trifocal lens technology.
Two new non-mydriatic cameras from Carl Zeiss Meditec use a high-resolution optical chain, delivering enhanced retinal details for more effective detection and management of eye diseases.
Analyses of data from the OASIS study confirm the efficacy of intravitreal ocriplasmin for the treatment of symptomatic vitreomacular traction/vitreomacular adhesion (VMT/VMA) and the importance of proper patient selection, said Peter K. Kaiser, MD.
A novel glaucoma monitoring system is being developed to guide providers in establishing personalized monitoring schedules that would help them avoid missing significant progression in glaucoma suspects or patients with open-angle glaucoma, said Joshua D. Stein, MD, MS.
Although research has led to improvements in understanding the pathophysiology of adenoviral conjunctivitis and in its diagnosis, there remains a need for further advances, said Anat Galor, MD.
A phase III gene therapy trial for Leber congenital amaurosis showed that patients’ mean mobility test scores promptly improved after treatment, and the benefit was sustained at 1 year, said Albert M. Maguire, MD.
Swept-source, microscope-integrated, ocular coherence tomography (SS-MIOCT) is a new investigational technology for real-time intraoperative imaging of the cornea and anterior segment, said Terry Kim, MD.
Pre-existing dry eye can affect the outcomes of excimer laser refractive and cause significant postoperative morbidity as well as patient dissatisfaction. Therefore, preoperative screening for dry eye is critical, said Michael B. Raizman, MD.
The prospect of an expanding armamentarium of corneal inlays for presbyopia correction is an exciting development, said Jay A. Pepose, MD, PhD.
Results from the Diabetic Retinopathy Clinical Research Network Protocol S provide evidence for the first major advance in the treatment of proliferative diabetic retinopathy (PDR) in more than 40 years, said Jeffrey Gross, MD.
The availability of a new cataract surgery platform from Abbott Medical Optics (AMO) marks the second phacoemulsification system launched by the company in the United States this year.
